Steven Feldman to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Steven Feldman has written about Tumor Necrosis Factor-alpha.
Connection Strength
2.448
-
Kazemi A, Cline A, Cardwell LA, Feldman SR. Psoriasis therapy and aortic inflammation - translating statistical to clinical significance. Dermatol Online J. 2018 Sep 15; 24(9).
Score: 0.587
-
Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-a inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014 Feb; 15(1):37-43.
Score: 0.426
-
Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-a inhibitors in psoriasis. J Drugs Dermatol. 2013 Mar; 12(3):e41-5.
Score: 0.400
-
Kaminska E, Patel I, Dabade TS, Chang J, Qureshi AA, O'Neill JL, Balkrishnan R, Feldman SR. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. J Dermatolog Treat. 2013 Apr; 24(2):101-6.
Score: 0.357
-
Wechter T, Seger EW, Cline A, Feldman SR. Can We Tell Patients That IL-23 and TNF-a Inhibition Are "Natural" Ways to Treat Psoriasis? J Cutan Med Surg. 2019 May/Jun; 23(3):337-338.
Score: 0.153
-
Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017 Dec; 152(6):586-596.
Score: 0.137
-
Smith J, Cline A, Feldman SR. Advances in Psoriasis. South Med J. 2017 01; 110(1):65-75.
Score: 0.130
-
Feldman SR. Message from the guest editor. J Drugs Dermatol. 2012 Aug; 11(8):906.
Score: 0.096
-
Sumner W, Feldman SR. Conversion to positive tuberculosis test during etanercept treatment of psoriasis. J Drugs Dermatol. 2007 Oct; 6(10):1048.
Score: 0.069
-
Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumab. Expert Opin Biol Ther. 2010 Jan; 10(1):133-52.
Score: 0.020
-
Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
Score: 0.020
-
Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008 Oct 02; 6:75.
Score: 0.018
-
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
Score: 0.018
-
Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
Score: 0.018